Abiopharma

🔍 Brown David Craig (Executive)

Company: Victory Capital Holdings, Inc. (VCTR)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 147,529 shares of Common Stock (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: false | shares_owned_after: 2,500,367.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 58,056 shares of Common Stock at $118.17 per share (Direct)
  Date: 2026-08-13 | Code: F | equity_swap_involved: false | shares_owned_after: 2,442,311.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 147,529 shares of Performance-based Restricted Stock (Derivative)
  Date: 2026-08-13 | Code: M | equity_swap_involved: false | shares_owned_after: 295,057.00 | transaction_form_type: 4 | Footnotes: F3, F4, F1, F5, F6

Footnotes:

• F1: Acquisition of Common Stock upon settlement of performance-based restricted stock. Each performance-based restricted stock represents a right to receive one share of Common Stock.
• F2: Represents shares of Common Stock withheld to satisfy the reporting person's tax obligation upon the vesting of performance-based restricted stock based on the closing price of the Company's shares on August 13, 2026.
• F3: As disclosed on a Form 8-K filed on March 16, 2026, performance-based shares of restricted stock (the "Performance Shares") were granted to the Reporting Person on March 15, 2026, pursuant to the, Amended and Restated Victory Capital Holdings, Inc. 2018 Equity Plan, with vesting tied to four significant stock price performance hurdles. Each Performance Share represents a contingent right to receive one share of Victory Capital Holdings, Inc., Common Stock.
• F4: Each performance-based restricted stock represents a contingent right to receive one share of Common Stock.
• F5: Performance Shares vested on August 13, 2026 following approval by the Compensation Committee of the Board of Directors of the Issuer of the achievement of the second stock price performance hurdle.
• F6: Not applicable.